CymaBay actively seeks partnerships as one part of a strategy to support our vision of improving the lives of patients with liver and other chronic diseases.
In December 2016, we entered into an exclusive licensing agreement with Kowa Pharmaceuticals America, Inc. (Kowa) for the development and commercialization of arhalofenate in the U.S. The arhalofenate program has completed Phase 2 development and is ready to advance to Phase 3. Kowa is responsible for all development and commercialization costs in the U.S. Under the terms of the agreement, CymaBay is eligible to receive milestones and royalties.
CymaBay retains full development and commercialization rights outside the U.S. and intends to partner in those geographies.
Please click here for inquiries regarding collaborations.